For 130 years, Merck (known as MSD outside of the U.S. and Canada) has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.
We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.
Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.
About the drug:
The combination drug (Sitagliptin Phosphate and Metformin HCl) is a prescription drug that comprises of two active ingredients one is Sitagliptin Phosphate and Metformin HCl in it. They together improve the blood glucose levels in type 2 diabetes. This drug is administered along with the diet and exercise and helps in lowering increased blood sugar levels of the body.
Sitagliptin is an oral medicine for diabetes. It is marketed as salt of phosphate under various brand names. It is a very effective medicine to control diabetes by controlling the sugar level. It is mostly recommended for type 2 diabetes mellitus alone or in combination with other medicines that cure diabetes. It is not recommended to treat type-1 diabetes. This drug is either sold alone or in combination with metformin or Thiazolidinediones (other anti-hyperglycemic agents).